Naslov
Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin- dependent kinase 4/6 inhibitors (CDK4/6i): Real world data.

Autori
Dedic Plavetic, Natalija ; Čular, Katarina ; Križić, Marija ; Popovic, Marina ; Plestina, Stjepko ; Silovski, Tajana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, prošireni sažetak, znanstveni

Izvornik
Journal of Clinical Oncology / - , 2023

Skup
ASCO 2023 American Society of Clinical Oncology Annual Meeting

Mjesto i datum
Chicago (IL), Sjedinjene Američke Države, 02.06.2023. - 06.06.2023

Vrsta sudjelovanja
Ostalo

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
breast cancer, HR+/HER2- subtype, PIK3CA gene mutation, cyclin-dependent kinase 4/6 inhibitors

Sažetak
BC is the most common malignant disease and leading cancer- related cause of death in women. Despite significant achievements in the treatment, advanced BC (aBC) is still an incurable disease. HR+/HER2- subtype accounts for 70% of all BC. One of the most common mutations in BC is the PIK3CA gene mutation which can induce endocrine and chemo- resistance. There was no relevant difference in TTF between two groups. However, PIK3CA mutated subgroup had more aggressive clinical features - more often presented with bone marrow infiltration and de novo aBC, statistically relevant OR 5.158 and 2.323 respectively, which is related to lower quality of life and highlights the importance of treatment improvement for this subgroup of pts.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA